

A study on development of lead antibodies targeting an immune checkpoint inhibitor refractory factor for metastatic melanoma

Korea University



ONCOLOGY	Hit
Product Type	Antibody
Indication	1st indication : Immune-refractory cancer, metastatic melanoma 2nd indication : Cancer
Target	ONCOKINE-2 (OK-2)
MoA(Mechanism of Action)	OK-2 → OK-2 receptor → ERK/AKT → immune-refraactory phenotype
Competitiveness	First In Class
Development Stage	Hit
Route of Administration	Parenteral - Intraperitoneal